Valiant Laborato

Market Cap: Micro Cap
Industry: Pharmaceuticals & Drugs
ISIN: INE0JWS01017
NSEID: VALIANTLAB
BSEID: 543998

INR

94.88

2.93 (3.19%)

BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 15.7 k

{
  "main_header": {
    "sid": 10039033,
    "name": "Valiant Laborato",
    "stock_name": "Valiant Laborato",
    "full_name": "Valiant Laboratories Ltd",
    "name_url": "stocks-analysis/valiant-laborato",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "94.88",
    "chg": 2.93,
    "chgp": "3.19%",
    "dir": 1,
    "prev_price": "91.95",
    "mcapval": "412.25 Cr",
    "mcap": "Micro Cap",
    "scripcode": 543998,
    "symbol": "VALIANTLAB",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE0JWS01017",
    "curr_date": "Apr 11, 12:53 PM",
    "curr_time": "00:06 AM",
    "bse_nse_vol": "15.7 k",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/valiant-laborato-10039033-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Valiant Laboratories Faces Financial Struggles Amid Significant Stock Volatility and Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/valiant-laboratories-hits-52-week-low-amid-continued-stock-decline-and-weak-fundamentals-1644285",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/ValiantLaborato_priceRelatedfactors_840789.png",
        "date": "2025-03-28 13:39:03",
        "description": "Valiant Laboratories has faced notable volatility, reaching a new 52-week low and continuing a downward trend. The company has struggled over the past year, with a significant decline in stock value and concerning financial metrics, including a negative Return on Equity and challenges in debt servicing."
      },
      {
        "title": "Valiant Laboratories Reaches All-Time Low Amid Ongoing Financial Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/valiant-laboratories-stock-hits-all-time-low-of-rs-76-84-amid-declining-performance-1643899",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/ValiantLaborato_priceRelatedfactors_839737.png",
        "date": "2025-03-28 13:22:30",
        "description": "Valiant Laboratories, a microcap in the Pharmaceuticals & Drugs sector, is experiencing notable trading activity as it approaches an all-time low. The stock has shown a downward trend, with significant declines over the past week and month, alongside weak long-term financial metrics and challenges in servicing its debt."
      },
      {
        "title": "Valiant Laboratories Hits 52-Week Low Amid Ongoing Financial Struggles and Market Scrutiny",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/valiant-laboratories-hits-new-52-week-low-amid-significant-stock-decline-2-1624805",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/ValiantLaborato_priceRelatedfactors_819409.png",
        "date": "2025-03-27 10:40:47",
        "description": "Valiant Laboratories, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, reflecting a 45.43% decline over the past year. The company faces significant financial challenges, including falling net sales and operating profit, alongside a negative EBIT to interest ratio and zero return on equity."
      },
      {
        "title": "Valiant Laboratories Hits 52-Week Low Amid Ongoing Financial Challenges and Market Pressures",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/valiant-laboratories-hits-52-week-low-amid-significant-financial-decline-and-strong-sell-rating-1624819",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/ValiantLaborato_priceRelatedfactors_819407.png",
        "date": "2025-03-27 10:40:43",
        "description": "Valiant Laboratories has reached a new 52-week low, reflecting a significant decline in its stock performance, with a one-year return notably below the broader market. The company faces financial challenges, including negative EBITDA and a weak return on equity, raising concerns about its operational viability and strategic direction."
      },
      {
        "title": "Valiant Laboratories Hits All-Time Low Amid Ongoing Financial Struggles and Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/valiant-laboratories-stock-hits-all-time-low-at-rs-79-01-amid-ongoing-decline-1624523",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/ValiantLaborato_priceRelatedfactors_819366.png",
        "date": "2025-03-27 10:27:28",
        "description": "Valiant Laboratories, a microcap in the Pharmaceuticals & Drugs sector, has faced significant volatility, recently nearing its all-time low. The stock has underperformed the broader market, with notable declines over various time frames. Financial metrics reveal weak fundamentals, including a negative EBIT to interest ratio and declining net sales."
      },
      {
        "title": "Valiant Laboratories Faces Significant Challenges Amidst Declining Stock Performance and Weak Fundamentals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/valiant-laboratories-hits-new-52-week-low-amid-significant-stock-decline-1601767",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/ValiantLaborato_priceRelatedfactors_798209.png",
        "date": "2025-03-26 10:40:33",
        "description": "Valiant Laboratories, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, reflecting a significant decline over the past year. The company faces challenges with weak fundamentals, including a 0% average Return on Equity and a negative EBIT to Interest ratio, indicating ongoing financial difficulties."
      },
      {
        "title": "Valiant Laboratories Faces Significant Financial Challenges Amidst Ongoing Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/valiant-laboratories-hits-52-week-low-amid-significant-stock-decline-and-weak-fundamentals-1601765",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/ValiantLaborato_priceRelatedfactors_798210.png",
        "date": "2025-03-26 10:40:30",
        "description": "Valiant Laboratories, a microcap in the Pharmaceuticals & Drugs sector, has hit a new 52-week low and has seen a significant decline over the past year. The company's financial health is concerning, with negative net profit and declining sales, alongside poor debt management indicators."
      },
      {
        "title": "Valiant Laboratories Hits All-Time Low Amid Ongoing Market Challenges and Weak Fundamentals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/valiant-laboratories-stock-hits-all-time-low-at-rs-79-6-amid-ongoing-decline-1601168",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/ValiantLaborato_priceRelatedfactors_797768.png",
        "date": "2025-03-26 10:12:15",
        "description": "Valiant Laboratories, a microcap in the Pharmaceuticals & Drugs sector, is facing significant challenges, reflected in its recent stock performance. The company has reached an all-time low, with notable declines in sales and profitability, alongside concerns regarding its debt management and overall market confidence."
      },
      {
        "title": "Valiant Laboratories Faces Challenges Amid Significant Stock Decline and Weak Fundamentals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/valiant-laboratories-hits-52-week-low-amid-significant-financial-struggles-and-declining-sales-1400462",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/ValiantLaborato_priceRelatedfactors_680789.png",
        "date": "2025-03-17 09:57:49",
        "description": "Valiant Laboratories has reached a new 52-week low, reflecting a significant decline over the past year, contrasting with broader market gains. The stock remains below key moving averages and has shown concerning financial metrics, including negative Return on Equity and declining net sales, indicating a challenging market environment."
      }
    ],
    "total": 26,
    "sid": "10039033",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/valiant-laboratories-10039033"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "26-Mar-2025",
      "details": "Closure of Trading Window for the quarter ended March 31 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Credit Rating",
      "datetime": "19-Feb-2025",
      "details": "Announcement under Regulation 30 regarding Credit Ratings issued to the Company",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "08-Feb-2025",
      "details": "Newspaper Publication of the Financial Results for the quarter ended December 31 2024.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Valiant Laboratories Faces Financial Struggles Amid Significant Stock Volatility and Decline

2025-03-28 13:39:03

Valiant Laboratories has faced notable volatility, reaching a new 52-week low and continuing a downward trend. The company has struggled over the past year, with a significant decline in stock value and concerning financial metrics, including a negative Return on Equity and challenges in debt servicing.

Valiant Laboratories Reaches All-Time Low Amid Ongoing Financial Challenges

2025-03-28 13:22:30

Valiant Laboratories, a microcap in the Pharmaceuticals & Drugs sector, is experiencing notable trading activity as it approaches an all-time low. The stock has shown a downward trend, with significant declines over the past week and month, alongside weak long-term financial metrics and challenges in servicing its debt.

Valiant Laboratories Hits 52-Week Low Amid Ongoing Financial Struggles and Market Scrutiny

2025-03-27 10:40:47

Valiant Laboratories, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, reflecting a 45.43% decline over the past year. The company faces significant financial challenges, including falling net sales and operating profit, alongside a negative EBIT to interest ratio and zero return on equity.

Valiant Laboratories Hits 52-Week Low Amid Ongoing Financial Challenges and Market Pressures

2025-03-27 10:40:43

Valiant Laboratories has reached a new 52-week low, reflecting a significant decline in its stock performance, with a one-year return notably below the broader market. The company faces financial challenges, including negative EBITDA and a weak return on equity, raising concerns about its operational viability and strategic direction.

Valiant Laboratories Hits All-Time Low Amid Ongoing Financial Struggles and Market Volatility

2025-03-27 10:27:28

Valiant Laboratories, a microcap in the Pharmaceuticals & Drugs sector, has faced significant volatility, recently nearing its all-time low. The stock has underperformed the broader market, with notable declines over various time frames. Financial metrics reveal weak fundamentals, including a negative EBIT to interest ratio and declining net sales.

Valiant Laboratories Faces Significant Challenges Amidst Declining Stock Performance and Weak Fundamentals

2025-03-26 10:40:33

Valiant Laboratories, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, reflecting a significant decline over the past year. The company faces challenges with weak fundamentals, including a 0% average Return on Equity and a negative EBIT to Interest ratio, indicating ongoing financial difficulties.

Valiant Laboratories Faces Significant Financial Challenges Amidst Ongoing Market Volatility

2025-03-26 10:40:30

Valiant Laboratories, a microcap in the Pharmaceuticals & Drugs sector, has hit a new 52-week low and has seen a significant decline over the past year. The company's financial health is concerning, with negative net profit and declining sales, alongside poor debt management indicators.

Valiant Laboratories Hits All-Time Low Amid Ongoing Market Challenges and Weak Fundamentals

2025-03-26 10:12:15

Valiant Laboratories, a microcap in the Pharmaceuticals & Drugs sector, is facing significant challenges, reflected in its recent stock performance. The company has reached an all-time low, with notable declines in sales and profitability, alongside concerns regarding its debt management and overall market confidence.

Valiant Laboratories Faces Challenges Amid Significant Stock Decline and Weak Fundamentals

2025-03-17 09:57:49

Valiant Laboratories has reached a new 52-week low, reflecting a significant decline over the past year, contrasting with broader market gains. The stock remains below key moving averages and has shown concerning financial metrics, including negative Return on Equity and declining net sales, indicating a challenging market environment.